Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against iRhythm Holdings, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is iRhythm Holdings, Inc. (IRTC) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of iRhythm Holdings, Inc. (NASDAQ: IRTC).
On November 5, 2026, iRhythm Holdings, Inc. reported third-quarter revenue of $221.6 million, below Wall Street consensus estimates, despite raising its full-year revenue guidance. During the Company’s earnings call, management also stated that it no longer expected to submit Zio MCT to the FDA in 2026 and that Zio AT revenue was flat and below its growth expectations. Management linked both developments to the integration of VitalConnect.
Following this news, iRhythm’s stock price fell as much as $43.89, or approximately 33.71%, during intraday trading on November 6, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether iRhythm Holdings, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether iRhythm Holdings, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should iRhythm Holdings, Inc. (IRTC) Investors Do?
How Is iRhythm Holdings, Inc. (NASDAQ: IRTC) Stock Trading Today?
Interactive chart showing the weekly share price history of NASDAQ:IRTC (NASDAQ:IRTC).
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”